DEPOSIT AGREEMENT by and among MOLECULAR PARTNERS AG and CITIBANK, N.A., as Depositary, and THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES ISSUED HEREUNDER Dated as of June 18, 2021Deposit Agreement • March 15th, 2022 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
DEPOSIT AGREEMENT, dated as of June 18, 2021, by and among (i) MOLECULAR PARTNERS AG, a corporation incorporated under the laws of Switzerland, and its successors (the “Company”), (ii) CITIBANK, N.A., a national banking association organized under the laws of the United States of America (“Citibank”) acting in its capacity as depositary, and any successor depositary hereunder (Citibank in such capacity, the “Depositary”), and (iii) all Holders and Beneficial Owners of American Depositary Shares issued hereunder (all such capitalized terms as hereinafter defined).
ContractLicense Agreement • March 15th, 2022 • Molecular Partners Ag • Biological products, (no disgnostic substances)
[ ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN NOVARTIS PHARMA AG AND MOLECULAR PARTNERS AGLicense and Collaboration Agreement • March 15th, 2022 • Molecular Partners Ag • Biological products, (no disgnostic substances) • New York
This LICENSE AND COLLABORATION AGREEMENT (“Agreement”) is made as of this 13th day of December 2021 (“Effective Date”), by and between Novartis Pharma AG, located at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”) and Molecular Partners AG, located at Wagistrasse 14, 8952 Zurich-Schlieren, Switzerland (“Licensor”). Novartis and Licensor are each referred to individually as a “Party” and together as the “Parties.”
